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INTRODUCTION 
Stroke is the leading cause of adult disability and is the second 
commonest cause of death worldwide[1].More than  two-thirds of the global 
burden of stroke is borne by developing countries, where the average age of 
patients with stroke is 15 years younger than in developed countries.[2]  The 
available data indicate that stroke occurring in young people is more often 
atherothrombotic in origin in developing countries,[3-5] in contrast to the 
developed countries where arterial dissection and cardioembolic etiologies 
predominate.[6-9] 
 
Ischemic stroke occurring in young Indians may be a manifestation of 
accelerated cerebrovascular atherosclerosis, paralleling the early age of onset 
of cerebrovascular diseases noted for this population.[10] Additionally based 
on prior data on increased propensity for insulin resistance among South 
Asians,[11,12] the ischemic stroke in young adults in India may be associated 
with the metabolic syndrome. 
 
The term metabolic syndrome refers to a cluster of metabolic 
abnormalities related to a state of insulin resistance.[13]The characteristics 
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include insulin resistance, abdominal obesity, elevated blood pressure(BP), 
triglycerides(TG)  and low levels of High density lipoprotein(HDL). 
 
To  assess the association between the metabolic syndrome (according 
to NCEP ATP III criteria)[14] and the acute ischemic non-embolic stroke a 
case control study was conducted, comparing 60 cases aged less than 45 
years with a first ischemic (non embolic) stroke with 30 controls of same age 
group without prior history of stroke and heart disease. 
 
Metabolic syndrome was diagnosed by using NCEP ATP III criteria 
except waist circumference. Cutoff point for abnormal waist circumference 
according to NCEP ATP III criteria is >102cm for males and >82cm for 
females. This may be fit for western population but it is very high for 
Indians. So the cutoff point for abnormal waist circumference was taken as 
per the new International Diabetes Federation(IDF) criteria where ethnic 
specific values were given. Cutoff point for South Asians as per the IDF 
criteria is >90cm for males and >80cm for females.    
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AIM OF THE STUDY 
 
To assess the association between the metabolic syndrome and its 
individual components- fasting blood sugar (FBS), blood pressure (BP), 
HDL cholesterol(HDL-C), triglyceride(TG) and waist circumference(WC) 
and the first ischemic (non embolic) stroke in young adults below 45 years. 
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REVIEW OF LITERATURE 
Stroke 
 
Stroke or cerebrovascular accident is defined as an acute onset of 
focal neurological deficit that is attributed to a vascular cause which lasts for 
more than 24 hours. It may be due to atherosclerotic thrombosis or embolism 
or hemorrhage-aneurysm, AV malformation etc. If the deficit recovers fully 
within 24 hours it is named as transient ischemic stroke (TIA). Typically the 
signs and symptoms of a TIA last for 5 to 15 minutes. 
 
Stroke is the leading cause of adult disability and the second 
commonest cause of death worldwide. More than two-thirds of the global 
burden of stroke is borne by developing countries. 
 
20-30% strokes in India occurs < 45years. There is widely recognized 
race and ethnic disparity in stroke patients in general. Young Blacks and 
Hispanics are having increased morbidity and mortality from stroke 
compared to Whites. 
  
Atherosclerosis remains the major cause not only for stroke but also 
for all vascular diseases. Moreover, current predictions estimate that by the 
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year 2020, atherosclerotic vascular diseases will become the leading global 
cause of total disease burden, defined as the years subtracted from healthy 
life by disability or premature death. 
 
METABOLIC SYNDROME 
 
Definition 
Metabolic syndrome refers to a cluster of metabolic abnormalities 
related to a state of insulin resistance which is often associated with obesity. 
The major characteristics include insulin resistance, abdominal obesity, 
elevated blood pressure and lipid abnormalities (elevated levels of 
triglycerides and low levels of high density lipoprotein (HDL-C) cholesterol. 
 
Metabolic syndrome is associated with proinflammatory and 
prothrombotic state that may include elevated levels of C- reactive protein, 
endothelial dysfunction, hyperfibrinogenemia, increased platelet aggregation 
increased levels of plasminogen activator inhibitor 1,elevated levels of uric 
acid, microalbuminuria and shift towards small, dense particles of low 
density lipoprotein cholesterol. 
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History 
The term "metabolic syndrome" dates back to at least the late 1950s, 
but came into common usage in the late 1970s to describe various 
associations of risk factors with diabetes, that had been noted as early as the 
1920s.[15,16] 
 The Marseilles physician Dr. Jean Vague, in 1947, observed that 
upper body obesity appeared to predispose to diabetes, 
atherosclerosis, gout, and calculi.[17]                                                                      
  Avogaro, Crepaldi and co-workers described six moderately obese 
patients with diabetes, hypercholesterolemia, and marked 
hypertriglyceridemia all of which improved when the patients were 
put on a hypocaloric, low carbohydrate diet.[18] 
 In 1977, Haller used the term "metabolic syndrome" for 
associations of obesity, diabetes mellitus, hyperlipoproteinemia, 
hyperuricemia and steatosis hepatis when describing the additive 
effects of risk factors on atherosclerosis.[19]  
 The same year, Singer used the term for associations of obesity, 
gout, diabetes mellitus, and hypertension with 
hyperlipoprotenemia.[20]  
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 In 1977 and 1978, Gerald B. Phillips developed the concept that 
risk factors for myocardial infarction concur to form a 
"constellation of abnormalities" i.e., glucose intolerance, 
hyperinsulinemia, hypercholesterolemia and hypertriglyceridemia 
and hypertension  that is associated not only with heart disease, but 
also with aging, obesity and other clinical states. He suggested 
there must be an underlying linking factor, the identification of 
which could lead to the prevention of cardiovascular disease; he 
hypothesized that this factor was sex hormones.[21,22] 
 In 1988, in his Banting lecture, Gerald M. Reaven proposed insulin 
resistance as the underlying factor and named the constellation of 
abnormalities as Syndrome X. Reaven did not include abdominal 
obesity, which has also been hypothesized as the underlying factor, 
as part of the condition.[23] 
The terms "metabolic syndrome," "insulin resistance syndrome," and 
"Syndrome X" are now used specifically to define a constellation of 
abnormalities that is associated with increased risk for the development of 
type 2 diabetes and atherosclerotic vascular disease. 
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Prevalence of Metabolic Syndrome in India and the World   
With the formulation of NCEP/ATP III guidelines, some uniformity 
and standardization has occurred in the definition of metabolic syndrome 
and has been very useful for epidemiological purposes. At present, 
metabolic syndrome is an all or none diagnosis. 
 The study results based on third National Health and Nutrition 
Examination Survey (NHANES III), showed that approximately one fourth of the 
US adults 20 years or older met the diagnostic criteria for metabolic syndrome.[24] 
The prevalence of the metabolic syndrome depends on age, ethnic background, 
and gender. It rises linearly from 20 to 50 years and plateaus thereafter. 
 
 Looking at various studies around the world, which included population 
samples, aged from 20 and onwards, the prevalence varies from 8% (India) to 
24% (United States) in men and from 7% (France) to 46% (India) in women.[25]  
 
Two Indian studies, which differed in their definition of obesity: first[26] 
used the obesity criteria suitable for Indians, while the second[27] used the 
standard ATP III definition of obesity. Both studies used population based 
samples within the age range but reported prevalence of 13% in Jaipur[27] and 
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41% in Chennai.[26] The prevalence of obesity in two study groups was quite 
similar (31% versus 33%), despite the different definitions used. Far larger 
differences were observed between the two studies for the prevalence of elevated 
triglycerides (46% vs. 30%), hypertension (55% vs. 39%) and elevated fasting 
plasma glucose (27% vs. 5%), each of which reported having used the same cut 
off points. 
Interestingly, a third Indian study,[28] also from Chennai, reported a 
metabolic syndrome prevalence of 11.2% (Using EGIR criteria), which was 
much closer to the prevalence rate reported for Jaipur than the other Chennai 
study. Therefore, even within the same ethnic population group it appears that 
there can be significant differences in the prevalence of both the individual 
factors that constitute the metabolic syndrome and the metabolic syndrome itself.  
 
               Metabolic syndrome prevalence rates as described earlier vary among 
ethnic groups as defined by the ATP III criteria among Finnish and Native 
American men. Both studies involved subjects with comparable age ranges (42-
60 and 44-49 years, respectively), with the Finnish study showing prevalence of 
only 14% compared with the prevalence in the Native American study of 43.6%. 
The prevalence varies from a low of 13.9% in black men to a high of 27.2% in 
Mexican American women.[29] 
10 
 
 
Causes of the metabolic syndrome   
Insulin resistance 
Insulin resistance and the metabolic syndrome appear to be almost 
inseparable. Insulin resistance was the basis of Reaven syndrome X and 
definitions of the metabolic syndrome required presence of insulin 
resistance. An elevated fasting blood glucose (used by some as a surrogate 
for insulin resistance) is one of the 5 components of the ATP III/AHA, 
NHLBI definition but any 3 conditions may be present for the diagnosis. 
Obesity 
           Fat deposition in the upper body, and particularly intra-abdominal fat 
(visceral adiposity), has been thought to have greater metabolic 
consequences than fat on the hips or thighs, which is more common in 
women.  Visceral adiposity is approximately 20% and 6% of total body fat 
in men and women, respectively. Unlike subcutaneous fat, blood circulation 
from visceral fat flows directly into the liver, thereby exposing it to high 
concentrations of free fatty acids and other chemicals and causing increased 
production of triglycerides and increased insulin resistance. 
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Obesity increases the risk of elevated fasting blood glucose or type 2 
diabetes, high triglycerides, elevated blood pressure or hypertension, and 
low HDL cholesterol. At the present, almost 25% of adults in the United 
States (about 47 million people) have the metabolic syndrome.  In non-
Western countries such as India in which obesity is on the rise, the metabolic 
syndrome soon follows.  
 The individuals who have fallen as victims to the obesity epidemic do 
not necessarily have abdominal obesity.  Therefore, it appears that 
abdominal obesity, while probably a great risk for the syndrome, is not an 
absolute requirement. Patients with normal blood glucose and weight who 
have an elevated blood pressure and triglycerides and a low HDL have, by 
definition, having the metabolic syndrome.  While such individuals compose 
a small number of all those with the metabolic syndrome, it seems that 
insulin resistance or an elevated blood glucose are not necessary for the 
diagnosis. 
Sedentary lifestyle 
   Sedentary lifestyle, that is, the lack of aerobic exercise is a major 
factor in the metabolic syndrome. But lack of exercise also tends to increase 
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weight, FBS, insulin resistance, blood pressure, and triglycerides.  With 
sufficient daily physical activity, the metabolic syndrome would disappear. 
Diet 
Diet high in refined carbohydrates (sweets, regular soda, juice, white 
flour, white potatoes) indirectly promotes the metabolic syndrome and leads 
to weight gain, increased triglycerides, and a low HDL.  Such diets are often 
high in sodium (salt), which increases the risk of high blood pressure. 
Age 
        Aging increases the incidence of high blood pressure and elevated 
blood glucose; and older individuals tend to be less physically active (which 
leads to higher blood pressure and blood glucose). 
Genetics 
Metabolic syndrome in the South Indian population has recently been 
reported to be associated with  Thr54 allele carriers of the Ala54Thr variant 
of FABP2 gene. 
Others 
Family history (Parents /siblings of DM 2) 
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Polycystic ovary syndrome  
  Pathogenesis 
The mechanisms underlying the metabolic syndrome are not fully 
known; however insulin resistance plays a fundamental role in the 
pathogenesis of metabolic syndrome. Resistance to insulin stimulated 
glucose uptake seems to modify the biochemical responses in a way that 
predisposes to metabolic risk factors.[30,31]  Insulin resistance causes lipolysis 
results in increased  plasma free fatty acid. This promotes hepatic VLDL 
release and lowers HDL cholesterol. Insulin resistance is associated with 
impairment of endothelial nitric oxide system thus results in 
vasoconstriction. Increased activity of sympathetic nervous system noted in 
the metabolic syndrome causes hypertension. 
 
A central role has been attributed to the pro-inflammatory cytokines, 
tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-6, that both are 
produced in substantial amounts by human adipose tissue. TNF- alpha 
impairs insulin-stimulated glucose uptake in a variety of cells and decreases 
lipoprotein lipase activity. Both cytokines increase hepatic lipogensis and 
elicit a systemic acute-phase response.[32] Increased hepatic release of 
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triglyceride rich VLDL results in insulin resistance by directly antagonizing 
insulin and inducing cytokines. 
 
Various aspects of the acute-phase response, such as fibrinogen and 
plasminogen activator inhibitor-1 levels, whole-blood viscosity, and white 
blood cell count, have recently been found to correlate positively with the 
metabolic syndrome.[33] This is of particular interest because inflammation 
plays an important role in the pathogenesis of atherothrombosis.[35] 
 
          Macrophage and T-cell infiltration is a major feature of atherosclerotic 
plaques, especially at the sites of plaque rupture, and epidemiological studies 
show strong positive associations of systemic markers of inflammation with 
atherothrombotic disease[34,36,37,38] Moreover, C-reactive protein (CRP), the 
classic and exquisitively sensitive acute phase reactant, shows a strong 
independent association with the risk of Coronary Heart Disease and other 
atherothrombotic events. CRP levels have also been found to correlate with 
BMI and some features of the metabolic syndrome. 
 
             Insulin resistance and resulting hyperinsulinemia have been 
implicated in the development of type 2 diabetes, hypertriglyceridemia, 
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hypertension, polycystic ovary syndrome, hypercoagulability and vascular 
inflammation, as well as the eventual development of atherosclerotic 
cardiovascular disease manifested as myocardial infarction, stroke and end 
organ damage. 
 
Signs and symptoms 
• Fasting hyperglycemia — diabetes mellitus type 2 or impaired fasting 
glucose, impaired glucose tolerance, or insulin resistance 
• High blood pressure 
• Central obesity (also known as visceral, male-pattern or apple-shaped 
adiposity), overweight with fat deposits mainly around the waist 
• Decreased HDL cholesterol 
• Elevated triglycerides 
Associated diseases and signs are: elevated uric acid levels, fatty liver 
(especially in concurrent obesity), progressing to non-alcoholic fatty liver 
disease, polycystic ovarian syndrome, hemochromatosis  and acanthosis 
nigricans.  
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Diagnostic criteria 
               There are currently two major definitions for metabolic syndrome 
provided by the International Diabetes Federation (IDF) and the Revised 
National Cholesterol Education Program (NCEP) respectively. The revised 
NCEP and IDF definitions of metabolic syndrome are very similar and it can 
be expected that they will identify many of the same individuals as having 
metabolic syndrome. The two differences are that IDF excludes any subject 
without increased waist circumference, while in the NCEP definition 
metabolic syndrome can be diagnosed based on other criteria and the IDF 
uses geography-specific cut points for waist circumference, while NCEP 
uses only one set of cut points for waist circumference regardless of 
geography. These two definitions are much closer to each other than the 
original NCEP and WHO definitions. 
WHO 
               The World Health Organization criteria (1999) require presence of 
diabetes mellitus, impaired glucose tolerance, impaired fasting glucose or 
insulin resistance  and two of the following: 
• blood pressure: ≥ 140/90 mmHg 
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• dyslipidaemia: 
   triglycerides  ≥1.695mmol/L(150mg/dl)    
   high density lipoprotein cholesterol 
         ≤ 0.9mmol/L (male) 
         ≤ 1.0 mmol/L (female) 
• central obesity 
         waist: hip ratio > 0.90 (male); > 0.85(female) and/or  
         body mass index > 30 kg/m2 
• microalbuminuria:  
        urinary albumin excretion ratio ≥ 20 mg/min or 
        albumin : creatinine ratio ≥ 30 mg/g 
The WHO criteria differed from all subsequent definitions in two 
respects:  
1) One of the risk factors was a measure of renal impairment based on the 
amount of protein excreted in the urine.  
2) Obesity was determined either by waist-to-hip ratio or body mass index. 
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EGIR 
The European Group for the Study of Insulin Resistance (EGIR) 
(1999) requires insulin resistance defined as the top 25% of the fasting 
insulin values among non-diabetic individuals and two or more of the 
following: 
1) Central obesity: 
          waist circumference ≥ 94 cm (male), ≥ 80 cm (female) 
2) Dyslipidaemia:  
          TG ≥ 2.0 mmol/L and /or  
          HDL-C < 1.0 mmol/L or 
          Treated for dyslipidaemia 
3) Hypertension:   
         Blood pressure ≥ 140/90 mmHg or on antihypertensive medication 
4) Fasting plasma glucose ≥ 6.1 mmol/L(110mg/dl) 
NCEP(2001): 
          In 2001, led by Dr. Scott Grundy, the National Cholesterol Education 
Program Adult Treatment Panel (ATP III) was published and became what 
is now probably the most widely used definition of the metabolic syndrome 
in the United States.  Neither the insulin resistance syndrome nor any other 
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single condition was a necessary component.  The risk factor used as a 
surrogate for insulin resistance could be either DM-2 or an impaired fasting 
plasma glucose level (IFG). 
The 2003 position statement by the American College of 
Endocrinology reasserted the primacy of insulin resistance and dropped the 
term metabolic syndrome. As in the earliest guidelines, insulin resistance 
was made a necessary component of the syndrome.  A specific number of 
other risk factors were not included- DM-2 was not  used in making the 
diagnosis and several clinical scenarios not included in other guidelines were 
added:  family history of DM-2, ethic groups prone to DM, sedentary 
lifestyle, advancing age, and polycystic ovary syndrome (a condition often 
accompanied by insulin resistance and its associated abnormalities). 
The US National Cholesterol Education Program Adult Treatment Panel III 
(2001) requires at least three of the following  
• central obesity: waist circumference ≥ 102 cm or 40 inches (male),  
                                                           ≥ 88 cm or 36 inches(female) 
• dyslipidaemia: TG ≥ 1.695 mmol/L (150 mg/dl) 
• dyslipidaemia: HDL-C < 40 mg/dL (male), < 50 mg/dL (female) 
• blood pressure ≥ 130/85 mmHg 
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• fasting plasma glucose ≥ 6.1 mmol/L (110 mg/dl) 
The new International Diabetes Federation (IDF) definition 
According to the new IDF definition, for a person to be defined as 
having the metabolic syndrome, he must have: 
Central obesity  
        defined as waist circumference > 94cm for Europid men and  > 80cm 
for Europid women, with ethnicity specific values for  other groups  plus any 
two of the following four factors: 
• raised triglyceride level: > 150 mg/dL (1.7 mmol/L), or specific 
treatment for this lipid abnormality 
• reduced HDL cholesterol: < 40 mg/dL (1.0 mmol/L) in males and < 
50 mg/dL (1.3 mmol/L) in females, or specific treatment for this lipid 
abnormality 
• raised blood pressure: systolic BP >  130 or diastolic BP > 85 mm Hg, 
or treatment of previously diagnosed hypertension 
• raised fasting plasma glucose (FPG) > 100 mg/dL (5.6 mmol/L), or 
previously diagnosed type 2 diabetes 
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The IDF also delineated multiple, ethnic specific values for waist 
circumference and defined more stringent criteria for whites of European 
descent. 
Europids:  
           The cut-off point for abnormal waist circumference decreased from 
102 cm (40 inches) to 94 (37 inches) in men and from 88 cm (35 inches) to 
80 (31.5 inches) for women.  The IDF conceded that in the USA, the ATP 
III values (male 102 cm, female 88 cm) are likely to continue to be used.  
Chinese and South Asians (based on Chinese, Malay, and Asian-Indian 
populations):   male > 90 cm, female > 80 cm. 
Japanese:   male > 85 cm, female > 90 cm 
 
2005 ATP III/AHA, NHLBI Diagnostic Criteria for the Metabolic 
Syndrome: 
            There is confusion as to whether the American Heart Association and 
National Heart, Lung, and Blood Institute intended to create another set of 
guidelines or simply update the NCEP ATP III definition. According to 
Scott Grundy, University of Texas Southwestern Medical School, Dallas, 
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Texas, the intent was just to update the NCEP ATP III definition and not 
create a new definition.[39] 
Any 3 of the following 5 conditions fulfils the definition of the 
metabolic syndrome (using abnormal FBG as currently defined) 
• Elevated waist circumference: 
           Men - Equal to or greater than 40 inches (102 cm) 
           Women - Equal to or greater than 35 inches (88 cm) 
• Elevated triglycerides:  
           Equal to or greater than 150 mg/dL 
• Reduced HDL  cholesterol: 
           Men - Less than 40 mg/dL 
           Women - Less than 50 mg/dL 
• Elevated blood pressure:  
           Equal to or greater than 130/85 mm Hg or use of medication     
           for hypertension 
• Elevated fasting glucose:  
           Equal to or greater than 100 mg/dL (5.6 mmol/L) or 
           use of medication for hyperglycemia 
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PARAMETERS TO DIAGNOSE METABOLIC SYNDROME 
The definitions and criteria discussed earlier provide the parameters 
for the diagnosis of the syndrome: 
• Fasting blood glucose (FBG) 
• Fasting triglycerides 
• HDL cholesterol 
These three components of the metabolic syndrome require a fasting 
blood test for both the glucose and triglyceride levels; that is, nothing should 
be eaten or drunk other than water for 10 to 12 hours preceding the test.  
 Blood pressure, measured by a clinician 
 Waist circumference, measured by a clinician 
 
Waist circumference measurement: 
NHLBI recommendation for waist measurement is quite precise: place 
a tape measure at the top of the right iliac crest (pelvis), circle the abdomen 
on a horizontal plane parallel to the floor, make the tape snug without 
compressing the skin, and measure at the end of a normal expiration. 
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        Other methods: measurement at the umbilicus, where the waist is 
narrowest; half-way between the last rib and the iliac crest;  narrowest point 
between the costal  margin and iliac crest. 
Why is waist circumference used instead of body mass index? 
        The definition of the metabolic syndrome uses waist circumference as a 
surrogate for central obesity. Body mass index (BMI), a ratio of weight to 
height (weight in kilograms divided by height in meters square), provides no 
indication of the location of fat deposits. BMI is used to categorize the 
weight. 
Body Mass Index Categories:            
• Underweight: below 18.5 
• Desirable weight: 18.5-24.9 
• Overweight: 25-29.5 
• Obese: 30-39.5 
• Severely obese: 40 or higher 
According to BMI categories, the overweight and obese reflect greater 
muscle mass and not fat (e.g. a body builder who develops a very large 
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muscle mass).  Those with a BMI in the obese range may not have visceral 
obesity, and those with visceral obesity may have a BMI less than 30. 
The waist-to-hip ratio, which   was the WHO criterion  for   visceral 
obesity, is another measure of the same condition:   
   Normal values 
                        women : less than 0.8;  
                        men      : less than 1.0.   
Hip measurement is less controversial than that of waist and is usually 
measured at the maximum circumference above the buttocks. 
Waist measurement indicates both too much fat and its central 
location. Central or upper body obesity probably poses a greater risk for 
CVD and DM-2. Central obesity is most accurately determined by imaging 
techniques such as direct measurement of visceral fat by computer assisted 
tomography or magnetic resonance imaging, which are expensive and 
impractical in clinical research.  
Treatment for the Metabolic Syndrome 
No specific treatment is recommended for the metabolic syndrome 
other than changes in lifestyle. Lifestyle changes would be promoted by 
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clinicians caring for individuals not only with diabetes and high blood 
pressure but also for those with mild increases that are now called 
prediabetes (fasting blood glucose 100 -125 mg/dL) and prehypertension 
(systolic blood pressure 130-139 or diastolic blood pressure (80-89). 
Therapeutic Lifestyle modification 
As the most frequent causes of the metabolic syndrome are obesity, 
sedentary lifestyle and poor diet, all the features of the metabolic syndrome 
will improve with lifestyle modification.[40] 
• Weight loss 
Weight loss or more specifically decrease the percent body fat.  
Weight loss improves insulin sensitivity, increases HDL cholesterol 
and decreases FBG, blood pressure and triglycerides. 
• Exercise [41-47] 
Frequent aerobic exercise will improve the same parameters as losing 
body fat.  The current suggested minimum regimen is at least 30 
minutes of brisk aerobic exercise (e.g. brisk walking) 4 days/week 
plus a modest amount of strength training. The optimal amount of 
aerobic exercise is 60 minutes 7 days/week. 
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• Diet 
  a) Fat[48-51]   
         Reduce the saturated fats. 
      Total fat intake should be 25-35% of total calories.   
      Low fat diets decrease triglycerides and increase HDL 
b) Carbohydrates [52,53] 
         Reduce the processed food and refined carbohydrates (e.g. sugar,   
      soft drinks, juice,desserts, white flour)  
      Add whole grains, fruit, vegetables 
c) Protein         
      Fish, preferably small fish low in mercury (sardines, herring, small  
      mackerel, salmon) 
• Reduce salt in diet[54,55] 
• Reduce alcohol 
   Alcohol increases appetite  and triglycerides 
Because the metabolic syndrome increases the risk of a CVD event, 
other risk factors for that condition should be addressed: 
 Avoid Smoking  
 Treatment for elevated LDL cholesterol 
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 Treatment for DM 
 Treatment for high blood pressure 
 
Medications 
Obesity 
            Rimonaband- It is a cannabinoid-1 receptor antagonist.It inhibits  
            intake of fatty foods. 
            Orlistat- It inhibits pancreatic lipase and reduces fat digestion. 
Insulin Resistance 
Weight reduction and increased physical activity will reduce insulin 
resistance.Two classes of drugs are currently available that reduce insulin 
resistance. These are metformin [56] and insulin sensitizers such as 
thiazolidinediones (TZDs).    
Hyperglycemia 
          When patients with metabolic syndrome develop type 2 diabetes, they 
are at high risk for atherosclerotic vascular diseases.All risk factors should 
be intensively reduced. In addition, glucose levels should be appropriately 
treated with lifestyle therapies and hypoglycemic agents as needed to keep 
hemoglobin A1c levels below guideline targets. 
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Atherogenic dyslipidemia 
          Although statins typically are recognized to be LDL-lowering drugs, 
they reduce all apolipoprotein B–containing lipoproteins. Clinical studies 
demonstrate that abnormal lipoprotein patterns are doubly improved by 
combined statin-fibrate therapy. 
Elevated Blood Pressure 
Hypertensive patients with metabolic syndrome deserve lifestyle 
therapies to reduce blood pressure. In addition, antihypertensive drugs 
should be used as recommended by hypertension guidelines. 
Prothrombotic state 
       No drugs are available that target PAI-1 and fibrinogen. An alternative 
approach to the prothrombotic state is antiplatelet therapy. For example, low-
dose aspirin reduces CVD events in both secondary and primary prevention. 
Thus, use of aspirin for primary prevention in patients with metabolic 
syndrome is promising. 
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ATP III Guidelines for the Treatment of Patients with Metabolic 
Syndrome  
            Targeted area                  Goal  
Treat LDL cholesterol first.  
CHD and CHD risk equivalent 
(10-year risk for CHD >20 percent) 
<100 mg per dL (<2.6 mmol per 
L) 
At least two risk factors  
(10-year risk <=20 percent) 
<130 mg per dL (<3.35 mmol per 
L) 
Institute weight control. 10 percent from baseline 
Institute physical activity. 30 to 40 minutes per day 
Monitor treatment of hypertension. <130/85 mm Hg 
Treat elevated triglyceride levels 
and low HDL cholesterol levels 
 
Goal of non-HDL cholesterol for 
patients with triglyceride levels of 
> 200 mg per dL   
High CHD risk: <130 mg per dL 
Intermediate CHD risk: <160 mg 
per dL Low CHD risk: <190 mg 
per dL 
ATP = Adult Treatment Panel; LDL = low-density lipoprotein; CHD = 
coronary heart disease; HDL = high-density lipoprotein 
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MATERIALS AND METHODS 
Study site 
This study was conducted in Government Royapettah Hospital, Chennai 
during the period  of  2006- 2008. 
 
Study Population: 
Cases: 
60 patients aged less than 45 years hospitalized with the history of first 
ischemic stroke were included. 
 
Inclusion Criteria: 
1. Subjects aged less than 45 years. 
2. Presented with first acute ischemic stroke-CT or/and MRI brain was 
taken for confirmation of ischemic stroke. 
 
Exclusion Criteria: 
1. Prior history of Stroke 
2. Hemorrhagic stroke 
3. Presentation to the hospital more than 6 months after the stroke onset. 
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4. Embolic stroke – complete cardiac evaluation & carotid Doppler was 
done to rule out embolic stroke. 
5.   Stroke due to intra cranial sinus thrombosis 
 
Controls: 
30 subjects from a community based sample of individuals aged less 
than 45 years without prior history of stroke and heart disease were included. 
 
Data collection: 
Data collection was done by using a structured proforma. BP, fasting 
blood sugar, fasting lipids were taken at approximately a week or later after 
stroke onset, as elevations in BP, blood sugar and lipids are well 
documented during the acute phase of stroke.[57,58]Waist circumference was 
measured at the highest point of iliac crest at the end of normal expiration. 
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RESULTS AND ANALYSIS 
Characteristics of study population were assessed and the values were 
expressed as mean + standard deviation except for age, sex and smoking. 
Prevalence of the individual risk factors and the metabolic syndrome in both 
groups were compared. 
 
The association between the metabolic syndrome and its individual 
components and stroke was    determined by the logistic regression analysis. 
Odds ratio and their 95% confidence intervals were assessed. 
 
  Significance was defined as P value <0.05 in all cases. 
 
Characteristics of the study population 
Stroke patients had high level of fasting blood sugar, BP, total 
cholesterol, triglycerides and increased waist   circumference   compared 
to control group. 
 
Stroke was common in males.73% stroke patients were males. Stroke 
was more prevalent in 40-45 yrs age group. 53% of stroke patients were in 
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the age group of 41-45yrs. 60% of stroke patients had metabolic syndrome 
and 10% of control group had metabolic syndrome. 
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Table no 1 
         CHARACTERISTIC FEATURES OF STUDY POPULATION 
Sl.no Characterestic 
feature 
 
Cases 
n – 60 
Control 
n – 30 
P value 
Male  44[73.30%] 24[80.00%]      1 Gender  
 
 
 
Female 16[26.70%] 06[20.00%]  
30-35 05[08.30%] 01[03.30%]  
36-40 23[38.30%] 11[36.70%]  
    2 Age 
group 
41-45 32[53.30%] 18[60.00%]  
    3 Smoking  
 
33[55.00%] 08[26.7%] <0.01 
    4 FBS 
 
115.73+28.11 90.73+18.30 <0.01 
    5 
 
Syst BP 127.00+16.19 116.00+11.92 <0.01 
    6 Dias BP 81.58+08.90 78.17+08.90 0.07 
    7 HDL 
 
42.62+08.44 46.63+09.12 0.04 
    8 
  
Total cholesterol 196.80+59.35 164.90+40.78 0.01 
    9 
 
Triglycerides 156.70+53.09 132.60+39.85 0.03 
   10 
 
W.C 82.53+11.43 80.40+20.27 0.53 
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  Table no 2 
  AGE DISTRIBUTION 
 
AGE GROUP CASES CONTROLS TOTAL 
30-35 05 01 06 
36-40 23 11 34 
41-45 32 18 50 
TOTAL 60 30 90 
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53.3% of stroke patients were in the age group of 41-45yrs 
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Table no 3  
GENDER DISTRIBUTION 
 
GENDER CASES CONTROLS TOTAL 
MALES 44 24 68 
FEMALES 16 06 22 
TOTAL 60 30 90 
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73.3% of stroke patients were males 
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    Table no 4 
   PREVALENCE OF SMOKING 
 
SMOKING CASES CONTROLS TOTAL 
SMOKERS 33 08 41 
NON SMOKERS 27 22 49 
Total 60 30 90 
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                  55% of stroke patients were smokers. 
                  p value 0.01 
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Table no 5 
PREVALENCE OF HIGH BLOOD SUGAR 
[FBS >100mg/dl or diabetic on treatment] 
BLOOD SUGAR CASES CONTROLS TOTAL 
HIGH BS 39 06 45 
NORMAL BS 21 24 45 
TOTAL 60 30 90 
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65% of stroke patients had high blood sugar. 
20%of control group had high blood sugar. 
P value <0.001 
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                                      Table no 6               
                   PREVALENCE OF HIGH BLOOD PRESSURE 
                       [BP >130/85mmHg or on anti hypertensive] 
BLOOD 
PRESSURE 
 CASES CONTROLS   TOTAL 
High BP 28 05 33 
Low BP 32 25 57 
Total 60 30 90 
 
                     
PREVALENCE OF HIGH BLOOD 
PRESSURE
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controls
 
                      46.7% of stroke patients had high BP. 
                      16.7% of control group had high BP. 
                       P value 0.005 
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Table no 7 
PREVALENCE OF LOW HDL-C IN MALES 
[Males <40mg/dl]  
HDL CASES CONTROLS TOTAL 
 <40mg/dl 20 05 25 
>40mg/dl 24 19 43 
Total 44 24 68 
 
                 
PREVALENCE OF LOW HDL-C IN MALES
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                      45.5% of stroke patients had low HDL. 
                      20.8% of control group had  low HDL. 
                       P value 0.04 
42 
 
Table no 8 
PREVALENCE OF LOW HDL-C IN FEMALES 
[Females <50mg/dl]  
HDL CASES CONTROLS TOTAL 
<50mg/dl 10 03 13 
>50mg/dl 06 03 09 
Total 16 06 22 
 
              
PREVALENCE OF LOW HDL-C IN 
FEMALES
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                     62.5% of stroke patients had low HDL. 
                     50% of control group had  low HDL. 
                      P value is not significant. 
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    Table no 9 
PREVALENCE OF HIGH TRIGLYCERIDES 
[TG>150mg/dl] 
TG CASES CONTROLS TOTAL 
HIGH 31 08 39 
NORMAL 29 22 51 
Total 60 30 90 
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                     51.7% of stroke patients had high TG. 
                     26.7% of control group had high TG. 
                      P value 0.02.   
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    Table no 10 
PREVALENCE OF INCREASED WAIST CIRCUMFERENCE IN 
MALES [>90cm for South Asian males according to IDF criteria] 
WAIST 
CIRCUMFERENCE 
CASES CONTROLS TOTAL 
HIGH 14 02 16 
NORMAL 30 22 52 
Total 44 24 68 
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                      31.8% of stroke patients had increased waist circumference. 
                      8.3% of control group had increased waist circumference. 
                      P value 0.03. 
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    Table no 11 
 
PREVALENCE OF INCREASED WAIST CIRCUMFERENCE IN 
FEMALES [>80cm for South Asian females according to IDF criteria] 
          WAIST 
CIRCUMFERENCE
CASES CONTROLS TOTAL 
HIGH 06 02 08 
NORMAL 10 04 14 
TOTAL 16 06 22 
                     
                       
PREVALENCE OF INCREASED WAIST 
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                     37.5% of stroke patients had increased waist circumference. 
                     33.3% of control group had increased waist circumference. 
                      P value is not significant. 
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                          Table no 12 
 PREVALENCE OF METABOLIC SYNDROME 
METABOLIC 
SYNDROME 
CASES CONTROLS TOTAL 
Present 36 03 39 
Absent 24 27 51 
Total 60 30 90 
                     
         
PREVALENCE OF METABOLIC 
SYNDROME
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60% of stroke patients had metabolic syndrome. 
10% of control group had metabolic syndrome. 
P value <0.01 
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    Table no 13 
  LOGISTIC REGRESSION ANALYSIS 
Association between the metabolic syndrome and its components and the 
acute ischemic stroke 
 
Sl.no Features Odds ratio 95% CI P value 
1 FBS>100mg/dl 4.05 1.810-8.84 0.01 
2 Syst BP>130mmHg 1.08 0.968-1.205 0.17 
3 Diast BP>85mmHg 1.02 0.848-1.221 0.85 
4 Low HDL 2.18 1.01-4.011 0.03 
5 TG>150mg/dl 1.00 0.990-1.022 0.38 
6 High WC 1.04 0.996-1.090 0.73 
7 Metabolic syndrome >3 9.60 2.022-19.97 0.01 
8 Smoking 8.01 0.97-13.02 0.02 
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DISCUSSION 
 
In this case control study, stroke patients had higher fasting blood 
sugar, BP, abnormal lipid profile and increased waist circumference 
compared to community controls. Stroke was more prevalent in the age 
group of 41-45yrs. 53.3% of stroke patients belong to 41-45 yrs. Incidence 
of the stroke increases as the age advances. Stroke was more prevalent in 
males than females. 73.3% of stroke patients were males and 26.7% were 
females. 
 
FBS was higher in stroke group than control group (115.73 VS 90.73, 
P value <0.01). Higher FBS was associated with 4 fold stroke risk (4 odds, 
 P value 0.01) compared to control group and statistically significant. Insulin 
resistance is the pathophysiological process underlying the clustering of  
vascular risk factors in the metabolic syndrome. 
 
BP was higher in stroke group than control group. The presence of 
hypertension was associated with increased risk of acute ischemic stroke. 
However, this association was not statistically significant because of the high 
rate of hypertension in the control group. It is well-documented that the 
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prevalence of hypertension rises with advancing age. For example, in the 
Framingham cohort study,[59]aged 70 to 79 almost 50% had borderline 
hypertension. Among metabolic syndrome components, hypertension is 
considered the least "metabolic. It is multifactorial in origin, with increasing 
arterial stiffness significantly contributing to systolic hypertension in the 
elderly. 
 
Dyslipidemia is a hallmark of the Metabolic Syndrome. Stroke 
patients had low HDL-C, high total cholesterol (TC) to HDL-C ratio and 
high triglyceride. HDL-C level was inversely related to the risk of ischemic 
stroke. The protective role of HDL-C was attenuated in the presence of 
metabolic syndrome. In a case control study involving 204 patients with 
acute ischaemic stroke of all ages from Madras, South India, the authors 
found that while low HDL cholesterol and high total cholesterol to HDL 
cholesterol ratio were more frequent among  patients.[60] 
 
      Abdominal obesity in association with metabolic syndrome carries 
high risk for stroke. Visceral fat is associated with insulin resistance than 
any other adipose tissue compartment. In this study stroke patients had 
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increased WC than the control group. But association with stroke risk was 
not statistically significant. 
 
    According to NCEP-ATP III presence of three or more components 
is defined as metabolic syndrome. In this study 60% of stroke patients had 
metabolic syndrome and it was associated with nine fold stoke risk which 
was statistically highly significant. (9 Odds, P value 0.01)  
 
      Smokers were associated with eight fold increased risk for stroke 
than nonsmokers which is statistically highly significant.(8 Odds, P value 
0.02).Smoking is an independent risk factor for stroke. 
 
       In this study, high fasting blood sugar, low HDL cholesterol, 
smoking and metabolic syndrome were associated with increased stroke risk  
which is statistically highly significant. 
   
         A case control study, conducted in 214 South Indian patients 
aged between 15-45 years with first acute ischemic stroke in Sri Chitra 
Trunal Institute, Trivandrum[61] showed high fasting blood sugar, 
hypertension and smoking were associated with increased stroke risk. High 
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FBS associated with 4 fold stroke risk; smoking associated with 8 fold 
stroke risk; Metabolic syndrome associated with 6 fold stroke risk than 
community control group. 
 
     The two case control studies from India that included ischemic 
stroke in all age groups suggested that Hypertension, Diabetes mellitus and 
smoking are important risk factors.[62]  
  
In the Baltimore–Washington Cooperative Young Stroke Study,[63] 
which compared 296 cases of incident ischaemic stroke among black and 
white adults aged 18–44 years with 1220 community based adults of the 
same age group, hypertension, diabetes mellitus and current smoking 
emerged as important risk factors.  
 
Melbourne Risk Factor Study,[64] where 201 patients with first onset 
stroke due to cerebral infarction aged 15–55 years compared with the same 
number of matched neighbourhood control subjects showed hypertension, 
diabetes mellitus, current smoking, heart disease and long term heavy 
alcohol consumption were major risk factors. Although observational studies 
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from Western countries have emphasised the preponderance of cardiogenic 
embolism, arterial dissection, procoagulant states and non-atherosclerotic 
vasculopathies as possible aetiologies, careful analytic comparisons have 
shown the importance of traditional risk factors in the pathogenesis of stroke 
in the young adults.  
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SUMMARY 
 
1. Prevalence of stroke increases as the age advances. 
2. Stroke was more prevalent in males than females. 
3. Stroke patients had high fasting blood sugar, high BP, elevated total 
cholesterol, triglyceride, low HDL-C and increased waist  circumference 
than control group. 
4. Metabolic Syndrome was more prevalent in stroke patients. 60% of 
stroke patients had metabolic syndrome ; 10% in control group. 
5. High FBS was associated with 4 fold stroke risk (4 odds, p 0.01) 
compared to control group. 
6. Low HDL-C was associated with 2 fold stroke risk (2 odds, p 0.03) 
compared to control group. 
7. Metabolic Syndrome was associated with 9.6 fold stroke risk (9.6 odds,  
p 0.01) compared to control group.                                              
8. Smoking was associated with 8 fold stroke risk (8 odds, p 0.02) 
compared to control group. 
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CONCLUSION 
 
1) Metabolic syndrome and its individual components (high FBS and low 
HDL-C) were associated with increased risk for ischemic stroke in young 
adults. 
2) Smoking is an independent risk factor for ischemic stroke. 
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ABBREVIATION 
 
1. FBS-fasting blood sugar 
2. BP-blood pressure 
3. HDL-C-high density lipoprotein cholesterol 
4. TC-total cholesterol 
5. TG-triglycerides 
6. WC-waist circumference 
7. NCEP ATP III-National Cholesterol Education Programe Adult  
Treatment Panel III 
8. IDF-International Diabetes Federation 
9. NHLBI-National Heart, Lung,Blood Institute 
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PROFORMA 
 
Name:                       Age/Sex:                       Occupation:      
Address:                                                                              I.P NO: 
Contact No:                                                                         D.O.A: 
Ref Dr:                                                                                 D.O.D:  
       
Chief complaints: 
 
 
Presenting illness: 
 
 
Past History: 
 
Treatment History: 
 
Personal History: 
 
Family History: 
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General Examination: 
Height: 
Weight: 
W.C.: 
Anemia: 
Jaundice: 
Clubbing: 
Cyanosis: 
Lymphadenopathy: 
Pedal Edema: 
Vitals: 
Temp: 
Pulse: 
BP: 
RR: 
JVP: 
 
Systemic examination: 
 
Respiratoy System: 
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Cardiovascular system: 
 
Abdomen: 
 
Central nervous system: 
 
 
Investigations: 
1. Complete Hemogram 
2. Fasting blood sugar 
3. Renal parameters – Blood urea, Serum Creatinine, Serum 
Electrolytes. 
4. Fasting Lipid profile 
5. ECG 
6. CXR 
7. CT Brain / MRI Brain 
8. Echocardiogram 
9. Carotid Doppler Study 
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      MASTER CHART 
Sl no Group Name Gender FBS DM BP HT HDL TG WC MS Smoking
1 1 KUMAR 1 0 0 0 0 1 0 0 0 1 
2 1 RAJESH 1 0 0 1 0 0 1 0 0 1 
3 1 VIMALA 2 1 1 0 0 1 0 0 0 0 
4 1 NAVEEN 1 0 0 0 0 0 0 0 1 1 
5 1 SUMAN 1 1 1 1 0 1 0 1 1 1 
6 1 GEETHA 2 1 1 0 0 1 1 1 1 0 
7 1 GOKUL 1 1 1 1 1 1 1 0 1 0 
8 1 HARISH 1 0 0 0 0 0 1 0 0 1 
9 1 ARUN 1 1 0 1 1 1 1 0 1 1 
10 1 SUDHA 2 1 1 1 0 1 0 0 1 0 
11 1 MOHAMMED 1 1 1 0 0 1 0 1 1 0 
12 1 MOHAN 1 0 0 0 0 0 0 0 0 1 
13 1 NANDHINI 2 0 0 1 1 1 1 0 1 0 
14 1 DINESH 1 0 0 0 0 0 1 0 0 1 
15 1 RAMESH 1 1 1 0 0 1 1 0 1 1 
16 1 GUNASEKAR 1 0 0 1 0 1 0 0 0 1 
17 1 GANESH 1 0 0 1 0 0 1 0 0 1 
18 1 ANTONY 1 1 1 0 0 1 0 1 1 1 
19 1 GANGA 2 0 0 1 0 1 1 0 1 0 
20 1 MANI 1 1 1 0 0 0 0 0 0 1 
21 1 YAMUNA 2 1 1 0 0 1 1 0 1 0 
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Sl no Group Name Gender FBS DM BP HT HDL TG WC MS Smoking
22 1 ARUL 1 1 0 1 1 1 1 0 1 0 
23 1 PRASATH 1 0 0 0 0 0 0 0 0 1 
24 1 KALYANI 2 1 0 1 1 1 1 0 1 0 
25 1 MUNUSAMY 1 1 0 1 1 1 0 0 1 0 
26 1 RAMASAMY 1 1 0 0 0 1 0 1 1 1 
27 1 SUDAR 1 0 0 0 0 0 0 0 0 1 
28 1 JAGAN 1 0 0 1 0 1 1 0 1 0 
29 1 SUNDARI 2 1 0 0 0 0 1 0 0 0 
30 1 SIVAJI 1 1 1 0 0 1 1 0 1 1 
31 1 KANNAN 1 1 1 0 0 1 1 0 1 1 
32 1 SANKAR 1 0 0 0 0 0 0 1 1 1 
33 1 JAYANTHI 2 1 0 1 1 0 1 1 1 0 
34 1 SHAMEEM 1 0 0 0 0 0 0 0 0 1 
35 1 SASIKUMAR 1 1 1 0 0 1 1 1 1 1 
36 1 JAMES 1 1 0 1 1 1 0 0 0 1 
37 1 VINOTH 1 1 1 1 0 1 0 0 0 0 
38 1 KUMUDHA 2 0 0 0 0 1 1 1 1 0 
39 1 HUSSAIN 1 1 0 1 1 0 0 1 1 0 
40 1 LALITHA 1 1 0 0 0 1 1 0 1 0 
41 1 SELVAN 1 1 1 1 0 0 1 0 1 1 
42 1 FATHIMA 2 0 0 0 0 1 1 1 1 0 
43 1 MARY 2 1 1 0 0 0 0 0 0 0 
44 1 KRISHNAN 1 0 0 1 0 0 0 1 0 1 
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Sl no Group Name Gender FBS DM BP HT HDL TG WC MS Smoking
45 1 SABAPATHY 1 1 0 1 0 0 0 0 0 1 
46 1 SUMATHI 2 1 0 1 1 0 1 0 1 0 
47 1 BOOPATHY 1 1 0 1 0 0 1 1 1 0 
48 1 GANAPATHY 1 0 0 0 0 0 0 0 0 1 
49 1 MURUGAN 1 1 0 0 0 0 0 1 0 0 
50 1 VIJAY 1 1 0 0 0 0 0 1 0 1 
51 1 LOGANADHAN 1 1 0 1 0 1 0 0 1 0 
52 1 JOHN 1 1 0 1 1 1 0 0 1 1 
53 1 BALA 1 0 0 0 0 0 1 1 0 1 
54 1 KUMARAN 1 0 0 0 0 0 0 0 0 1 
55 1 SRIKUMARAN 1 1 0 0 0 0 1 1 1 0 
56 1 GOMADHI 2 1 0 1 0 0 0 0 0 0 
57 1 AMALA 2 1 0 1 1 0 1 1 1 1 
58 1 STEPHEN 1 1 0 1 0 0 1 0 1 1 
59 1 NARMADHA 2 1 0 0 0 1 1 1 1 0 
60 1 SEENU 1 1 0 0 0 0 1 1 1 1 
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Sl no Group Name Gender FBS DM BP HT HDL TG WC MS Smoking
1 0 DIVYA 2 0 0 0 0 0 0 1 0 0 
2 0 FEDRIK 1 0 0 0 0 0 0 0 0 0 
3 0 GOKUL 1 0 0 0 0 1 0 0 0 0 
4 0 VISU 1 0 0 0 0 0 0 0 0 0 
5 0 KAMALI 2 1 1 0 0 0 0 0 0 0 
6 0 NARESH 1 0 0 1 1 0 0 0 0 0 
7 0 ANAND 1 0 0 0 0 0 1 0 0 0 
8 0 PARUTHI 1 1 0 0 0 1 1 0 1 0 
9 0 JACK 1 1 0 0 0 0 1 0 0 0 
10 0 BAGAT SINGH 1 0 0 0 0 0 0 0 0 0 
11 0 ANURADHA 2 0 0 1 0 1 0 0 0 0 
12 0 VELU 1 0 0 9 0 0 0 1 0 0 
13 0 RAJA 1 0 0 9 0 0 0 0 0 1 
14 0 RATHNAM 1 0 0 9 0 0 0 0 0 0 
15 0 SHANMUGAN 1 0 0 9 0 0 0 0 0 1 
16 0 MATHI 1 0 0 9 0 0 0 0 0 0 
17 0 NALINI 2 1 1 1 1 1 1 0 1 1 
18 0 AZHAGAN 1 0 0 0 0 1 0 0 0 0 
19 0 ASOK 1 1 0 0 0 0 1 0 0 1 
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Sl no Group Name Gender FBS DM BP HT HDL TG WC MS Smoking
20 0 VIVEK 1 0 0 0 0 0 0 0 0 1 
21 0 RUPA 2 0 0 1 0 1 1 0 1 0 
22 0 NAGARAJ 1 0 0 0 0 0 0 0 0 1 
23 0 RAMAN 1 0 0 0 0 0 0 0 0 0 
24 0 PRIYA 2 0 0 0 0 0 0 1 0 0 
25 0 THILAK 1 1 1 0 0 0 1 0 0 0 
26 0 SEETHARAM 1 0 0 0 0 0 0 0 0 0 
27 0 RAJARAMAN 1 0 0 0 0 0 0 0 0 1 
28 0 BARANI 1 0 0 1 1 1 1 0 0 1 
29 0 GNANASUNDAR 1 0 0 0 0 1 0 0 0 0 
30 0 PALANI 1 0 0 0 0 0 0 1 0 0 
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KEY TO MASTER CHART 
Group 
         1- cases 
         2- controls 
Gender  
          1- males 
          2- females 
Age group 
          1- 31-35yrs  
          2- 36-40yrs  
          3- 41-45yrs 
FBS-fasting blood sugar 
          0- <100mg/dl 
          1- >100mg/dl 
DM-Diabetes Mellitus 
          0- not a known diabetic 
          1- known diabetic on treatment 
BP-Blood Pressure 
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          0- <130/85mmHg 
          1- >130/85mmHg 
HT-Hypertension 
          0- not a known hypertensive 
          1- known hypertensive on treatment 
HDL- high density lipoprotein 
          0-  >40mg/dl in males 
                >50mg/dl in females 
          1-  <40mg/dl in males 
                < 50mg/dl in females 
TG-triglycerides 
          0- <150mg/dl 
          1->150mg/dl 
WC-waist circumference 
          0-<90cm in males 
              < 80cm in females 
          1-  >90cm in males 
               >80cm in females 
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MS-metabolic syndrome  
          0- absent 
          1- present 
Smoking 
          0- absent 
          1- present 
